EA
NTLA icon

Edge Advisors’s Intellia Therapeutics NTLA Stock Holding History

Edge Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$27K Buy
+1,000
New +$24.2K ﹤0.01% 597

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Edge Advisors's NTLA Position: Q2 2018 in Review

Edge Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2018: 1,000 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #597 among its holdings.

156 funds tracked by Wall St. Rank hold NTLA as of Q2 2018.

  • Edge Advisors held 1,000 shares of Intellia Therapeutics worth $27K as of Q2 2018.
  • Intellia Therapeutics was a new Edge Advisors position in Q2 2018.
  • Intellia Therapeutics made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #597 holding.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.